July 3 (Reuters) - Gilead Sciences Inc:

* EUROPEAN COMMISSION GRANTS CONDITIONAL MARKETING AUTHORIZATION FOR GILEAD’S VEKLURY® (REMDESIVIR) FOR THE TREATMENT OF COVID-19

* GILEAD SCIENCES - UNDER AUTHORIZATION, VEKLURY IS INDICATED FOR TREATMENT OF COVID-19 IN ADULTS AND ADOLESCENTS WITH PNEUMONIA REQUIRING SUPPLEMENTAL OXYGEN

* GILEAD SCIENCES INC - CONDITIONAL MARKETING AUTHORIZATION IN EUROPE FOR VEKLURY (REMDESIVIR) IS INITIALLY VALID FOR ONE YEAR Source text for Eikon: Further company coverage:

Source: Reuters

Powered by NewsAPI.org